You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Dominick C. Colangelo

Director, President & Chief Executive Officer at Vericel Corp.
Overview
Relationships
In The News
Paths
Education
Career History
Boards & Committees
Public Holdings
Transactions

Dominick C. Colangelo

Director, President & Chief Executive Officer at Vericel Corp.

Overview

Primary Location
Indianapolis, IN, United States
Age
53 (Born 1965)
Notable Companies
Vericel Corp.

Promedior, Inc.
Board Seats
2
Number of Relationships
This person is connected to 900 people.

Relationships See Details


Co-Founder at QuatRx Pharmaceuticals Co.

President, Chief Executive Officer & Director at Emisphere Technologies, Inc.

Chief Strategy Officer at Vineti, Inc.

Senior Vice President, Chief Financial Officer & Treasurer at Acceleron Pharma, Inc.

Former Senior Vice President & Chief Scientific Officer at Warner-Lambert Co.

President, Chief Executive Officer & Director at Sigilon, Inc.

Chairman & Chief Executive Officer at ContraFect Corp.

Former Executive Director-Alliance Management at Eli Lilly & Company

Founder at Trellis Bioscience LLC

Co-Founder at SetPoint Medical Corp.
See 890 more listings with RelSci Professional.

In The News See More

GlobeNewswire
January 10, 2018
Marketwired
November 21, 2017
GlobeNewswire
November 16, 2017
GlobeNewswire
November 7, 2017
GlobeNewswire
September 27, 2017
See full news coverage and complete stories with RelSci Professional.

Paths to Dominick C. Colangelo

Dominick C. Colangelo
You
Connections via Relationship Science
Dominick C. Colangelo
Sync your contacts to see how you can connect with Dominick C. Colangelo.

Educational Background

BS 
Class of 1986 
University at Buffalo, The State University of New York, also commonly known as the University of Buffalo (abbreviated UB), University of Buffalo or SUNY Buffalo, is a public research university with multiple campuses located in Buffalo and Amherst, New York, United States. The university was founded in 1846 as a private college, but in 1962 was absorbed into the State University of New York (SUNY) system. By enrollment, UB is the largest of SUNY's four comprehensive university centers, and also the largest public university in the northeastern United States (comprising New York state and the New England region). In addition, by either endowment or research funding, UB is also the largest one of SUNY's four comprehensive flagship university centers.
 
Duke University School of Law (also known as Duke Law School or Duke Law) is the law school and a constituent academic unit of Duke University, Durham, North Carolina, United States. One of Duke's 10 schools and colleges, the School of Law began as the Trinity College School of Law in 1868.
Graduate Degree 
Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Career History

Director, President & Chief Executive Officer
2013 - Current
Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products in the United States of America, Carticel autologous cultured chondrocytes, an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel cultured epidermal autografts, a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
President, Chief Executive Officer & Director
2008 - 2012
Promedior, Inc. operates as a clinical-stage immunotherapy company that develops targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique anti-fibrotic immunotherapy mechanism to activate a regulatory switch upstream in the fibrosis cascade. The company was founded by Richard H. Gomer and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.
Managing Director
Prior - 2005
Lilly Ventures Management Co. focuses on investments in the biotechnology, medical technology and healthcare information technology sectors. The firm manages four funds: the e.Lilly Venture Fund, the Lilly BioVenture Fund, the Lilly MedTech Venture Fund and the Lilly Asian Ventures Fund.The e.Lilly Venture Fund targets investments in early- to development-stage start-up companies with e-business solutions that focus on the research, development and commercialization of pharmaceuticals. Investments range up to $3 million.The Lilly BioVenture Fund invests in early-stage biotechnology companies with pioneering drug discovery and development technologies and novel therapies.The Lilly MedTech Venture Fund targets investments in companies that are developing emerging technologies in the medical technology sector. The fund targets companies with innovative diagnostic technologies and therapeutic devices and combination products incorporating pharmaceuticals, medical devices or diagnostics. Initial investments range up to $5 million.The Lilly Asian Ventures makes venture capital investments in life science companies with strong management teams and innovative technology and/or business models. The fund targets companies at various stages of development from start-up to commercialization. Specific areas of interest include biotechnology and pharmaceuticals, medical devices and diagnostics and healthcare services. Their focus is mainly on opportunities in China but they will consider investment opportunities elsewhere in east and south Asia.
Executive Vice President-Corporate Development & Operations
2005 - 2008
Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded in 1961 and is headquartered in Waltham, MA.
Director, Strategy & Business Development
1995 - Prior
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. It operates through the Human Pharmaceutical Products and Animal Health segments. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Boards & Committees

Corporate Boards ▾
Member, Board of Directors
2013 - Current
Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products in the United States of America, Carticel autologous cultured chondrocytes, an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel cultured epidermal autografts, a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
President, Chief Executive Officer & Director
2008 - 2012
Promedior, Inc. operates as a clinical-stage immunotherapy company that develops targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique anti-fibrotic immunotherapy mechanism to activate a regulatory switch upstream in the fibrosis cascade. The company was founded by Richard H. Gomer and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Public Holdings

Restricted data only for RelSci Professional users.

Transactions

Details Hidden
Promedior, Inc. raised money in a private placement transaction
Details Hidden
Promedior, Inc. raised money in a private placement transaction
Details Hidden
Promedior, Inc. raised money in a private placement transaction

Other Affiliations

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.